Auriga Reiterates a 'Buy' on Illumina (ILMN) as '11 Ends Well & '12 Guidance Solid; Rejects Roche's Offer
ILMN Hot Sheet
Rating Summary:7 Buy, 11 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 2
Auriga reiterates a 'Buy' on Illumina (NASDAQ: ILMN) price target of $60.00.
Auriga analyst said, "Revenue continues to be drive by a recovery in instrument demand (+11% sequentially) and steady consumable demand. Management also provided detailed 2012 guidance that came in above the current consensus. ILMN has a number of key product launches planned for 2012, which should continue to drive demand and help offset the weakness within the Academic setting. ILMN also announced its board unanimously rejected Roche's unsolicited tender offer as inadequate, noting the current $44.50 per share offer undervalues the long term potential of the company."
For an analyst ratings summary and ratings history on Illumina click here. For more ratings news on Illumina click here.
Shares of Illumina closed at $51.80 yesterday, with a 52 week range of $25.57-$79.40.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
Auriga analyst said, "Revenue continues to be drive by a recovery in instrument demand (+11% sequentially) and steady consumable demand. Management also provided detailed 2012 guidance that came in above the current consensus. ILMN has a number of key product launches planned for 2012, which should continue to drive demand and help offset the weakness within the Academic setting. ILMN also announced its board unanimously rejected Roche's unsolicited tender offer as inadequate, noting the current $44.50 per share offer undervalues the long term potential of the company."
For an analyst ratings summary and ratings history on Illumina click here. For more ratings news on Illumina click here.
Shares of Illumina closed at $51.80 yesterday, with a 52 week range of $25.57-$79.40.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- UBS Maintains a 'Neutral' on National Financial Partners (NFP); Expect Near-Term Headwinds to Persist
- UPDATE: UBS Downgrades Avon Products (AVP) to Sell; Still Cautious Even After Sell Off
- Canaccord Genuity Reiterates a 'Buy' on Foot Locker (FL); In Full Stride; Raising PT
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
AurigaSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
